

## **Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC**

**Leuven, BELGIUM, Boston, MA, US – May 3, 2023 – 9.00 PM CET** [Oxurion NV](#) (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation<sup>1</sup> it has received a transparency notification as follows:

Oxurion received a transparency notification on April 28, 2023, from Atlas Special Opportunities LLC indicating that as of April 25 2023, it held 7,361,778 shares of the then outstanding 659,387,625 shares, and therefore crossed below the threshold (3%) by virtue of sale of voting securities. See Annex 1.

### **About Oxurion**

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at [www.oxurion.com](http://www.oxurion.com).

### ***Important information about forward-looking statements***

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

**For further information please contact:**

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10</p> <p>" <a href="mailto:tom.graney@oxurion.com">tom.graney@oxurion.com</a></p> <p>Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 <a href="mailto:michael.dillen@oxurion.com">michael.dillen@oxurion.com</a></p>	<p><u>US</u> <u>Conway Communications</u> Mary T. Conway <a href="mailto:mtconway@conwaycommsir.com">mtconway@conwaycommsir.com</a></p> <p><u>ICR Westwicke</u> Christopher Brinzey Tel: +1 617 835 9304 <a href="mailto:Chris.Brinzey@westwicke.com">Chris.Brinzey@westwicke.com</a></p>
---	---

---

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

# ANNEX 1

### 1) Status of the notification

Final

### 2) Issuer

Name OXURION  
Identification number 0881-620-924

### 3) Reason for the notification

Acquisition or disposal of voting securities or voting rights	-
Downward crossing of the lowest threshold	+

### 4) Notification by

A person that notifies alone

### 5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

### 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


**Part II**

### 7) Date on which the threshold is crossed

25/04/2023 (DD/MM/YYYY)

### 8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

659,387,625

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holder of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	15,407,185	7,361,778	0	1.12%	0.00%
<b>TOTAL</b>		<b>7,361,778</b>		<b>1.12%</b>	

Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.



uSign Envelope ID: 235F7CC9-F3BF-4DE8-8243-1321C537A75C

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
<b>TOTAL</b>						

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	<b>CALCULATE</b>	7,361,778	1.12%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  0 voting rights as of  (DD/MM/YYYY)

13) Additional information

Atlas held 15,407,185 voting rights in Oxurion on 12/04/2023 but subsequently sold these shares.  
On 24/04/2023, Atlas Special Opportunities LLC converted 21,934,100 shares and subsequently sold 2,504,515 of those shares in Oxurion NV on the same date. To be noted, while the conversion and sale occurred on 24/04/2023, the notary meeting relating to the conversion of the shares was held on 25/04/2023 and Atlas Special Opportunities LLC wasn't marked as officially having received the shares until 25/04/2023.  
On 25/04/2023, Atlas Special Opportunities LLC sold 12,067,807 additional shares in Oxurion NV.

Done at  New York

On  28/04/2023 (DD/MM/YYYY)

Name & capacity  Patrick Vance, proxyholder

Designated by:  Signature *Patrick Vance*  
5534B237829544C...